Screening Platforms for Biologics and Antibody Discovery

Biologics screening has become one of the most strategically important activities in modern pharmaceutical research, underpinning the discovery of the monoclonal antibodies (mAbs), bispecific antibodies, and fusion proteins that now constitute a dominant share of late-stage clinical pipelines. With over 100 monoclonal antibodies approved globally for therapeutic use, and hundreds more in development across oncology, immunology, and rare diseases, the demand for robust, high-throughput antibody discovery platforms has never been greater. The continued expansion of the biologic drug development pipeline requires screening technologies capable of interrogating libraries of millions to billions of protein variants to identify candidates with the required binding affinity, selectivity, and developability.¹

The landscape of antibody discovery platforms has diversified substantially over the past two decades. In vitro display technologies — principally phage display, yeast display, and ribosome display — provide the foundation for library-based screening of protein therapeutics. These are increasingly complemented by single-cell functional screening methods, microfluidic systems, and artificial intelligence-assisted candidate selection, reflecting the growing complexity of the biologic modalities now entering clinical development.²

Phage display: the established foundation of antibody discovery

Phage display, first described by George Smith in 1985 and applied to antibody engineering by McCafferty and Winter in 1990, remains the most widely used in vitro selection technology for antibody discovery platforms. The method works by fusing antibody fragments — typically single-chain variable fragments (scFv) or antigen-binding fragments (Fab) — to coat proteins of filamentous bacteriophage, creating a physical link between the displayed protein and its encoding gene. Iterative rounds of selection against an immobilized or soluble antigen, known as panning, enrich binders from libraries that can encompass up to 10¹¹ variants.³

Phage display has contributed directly to the approval of multiple therapeutic antibodies, including adalimumab and belimumab, and more than 70 phage-derived antibodies have entered clinical trials. Its key advantages include large library diversity, operation entirely in vitro without the need for animal immunization, and compatibility with automated, high-throughput panning workflows. Limitations include the use of prokaryotic expression systems that cannot perform mammalian post-translational modifications, which can affect the functional properties of complex glycoproteins.³

Yeast and ribosome display for protein therapeutics screening

Yeast surface display addresses a key limitation of phage display by exploiting the eukaryotic folding machinery of Saccharomyces cerevisiae. Antibody fragments are displayed as fusions to the yeast cell-wall protein Aga2p, allowing the expressed protein to undergo disulfide bond formation and partial glycosylation in a cellular environment more representative of the mammalian production host. The principal advantage of yeast display for protein therapeutics screening is its compatibility with fluorescence-activated cell sorting (FACS), enabling multiparameter quantification of binding affinity and antigen occupancy at the single-cell level.²

Yeast display libraries are typically constrained to 10⁷–10⁹ variants due to transformation efficiency limitations, several orders of magnitude smaller than phage display. Ribosome display circumvents this by operating entirely cell-free: ribosomes stall on messenger RNA lacking a stop codon, maintaining a ternary complex of mRNA, ribosome, and displayed protein that can be selected directly. This approach can generate libraries exceeding 10¹⁴ variants — the largest diversity accessible in any current in vitro selection system — making it particularly well-suited for the discovery of rare binders against difficult targets. The technical demands of ribosome display, including sensitivity to nuclease contamination and the requirement for optimized translation conditions, have limited its adoption relative to cell-based platforms.

Table 1. Comparison of major antibody discovery platforms by library diversity, key advantages, and primary limitations.

Single B-cell screening and immune repertoire approaches

Single B-cell screening methods provide an alternative to display technologies that offers access to full-length, affinity-matured antibodies from immunized animals or human donors. Rather than constructing synthetic libraries, these approaches isolate individual antigen-specific B cells from blood or lymphoid tissue using antigen-conjugated probes, then recover paired heavy- and light-chain variable region sequences by single-cell reverse transcription polymerase chain reaction (RT-PCR) or next-generation sequencing. The resulting antibodies reflect the natural affinity maturation process of the immune system, often yielding high-affinity candidates with favorable biophysical properties and reduced risk of developability liabilities.³

The integration of next-generation sequencing with B-cell receptor repertoire analysis — sometimes termed immune repertoire mining — has further expanded the utility of this approach. Deep sequencing of peripheral blood B-cell populations from immunized donors or convalescent patients enables the identification of convergent antibody clones associated with protective immune responses, providing starting material for lead optimization campaigns in biologics screening. These methods are increasingly applied in the rapid response to emerging infectious diseases, where speed of candidate identification is critical.

Functional screening for bispecific antibodies and complex biologics

The growing clinical importance of bispecific antibodies (bsAbs) — which engage two distinct antigens or epitopes simultaneously — has created demand for biologics screening platforms specifically designed to assess function rather than binding alone. Conventional monospecific screening workflows identify individual antibody arms against each target before combining them into bispecific formats at a late stage of development, limiting the diversity of bispecific combinations evaluated. Single-cell-based functional screening pipelines now enable combinatorial bispecific libraries to be interrogated directly for the desired mode of action, such as T-cell engagement or receptor co-clustering, identifying functional bsAb candidates at throughputs exceeding one million variants per screening run.⁴

Miniaturized and automated platforms for bispecific production and screening have been developed to address the bottleneck of expressing and purifying sufficient material for functional assays across large combinatorial matrices. Protein bioconjugation technologies — including controlled Fab-arm exchange (DuoBody), SpyTag/SpyCatcher ligation, and sortase-mediated assembly — allow bispecific molecules to be assembled in a plug-and-play manner from monospecific antibody fragments, enabling unbiased combinatorial screening of target pairs and biparatopic combinations without the need for dedicated bispecific expression constructs for each candidate.⁵

Key applications of functional biologics screening platforms include:

• T-cell engager (TCE) bispecific screening: identifying CD3-binding arms that activate cytotoxic T cells against tumour-associated antigens
• Checkpoint inhibitor combination screening: evaluating simultaneous blockade of immune checkpoints such as PD-1, CTLA-4, and LAG-3
• Antibody-drug conjugate (ADC) linker-payload optimization: assessing internalization efficiency and cytotoxic payload delivery in target-expressing cell lines
• Receptor degrader identification: screening for antibodies that drive receptor downregulation through lysosomal targeting

Developability assessment in the biologics screening workflow

A persistent challenge in biologic drug development is the gap between early-stage binding activity and downstream manufacturability. Antibodies that perform well in initial biologics screening assays frequently exhibit developability liabilities — including aggregation propensity, polyreactivity, high viscosity at therapeutic concentrations, or poor thermal stability — that preclude clinical advancement. Integrating developability assessment tools early in the screening cascade has therefore become a standard practice in industrial antibody discovery, enabling triage of leads before investment in full protein expression and purification.⁶

Tech Spotlight: High-Throughput Screening 2026

Explore reliable high-throughput screening workflows for vaccine and antibody discovery, covering assay design, validation and data analysis to improve reproducibility, data quality and candidate prioritization.

View Webinar

Advertisement

Biophysical developability panels typically include dynamic light scattering for hydrodynamic size and aggregation assessment, differential scanning fluorimetry for thermal stability profiling, polyspecificity reagent binding assays, and self-interaction chromatography. In silico developability scoring tools, trained on datasets of approved therapeutics, can prioritize sequences with favorable physicochemical profiles from computational predictions of solubility, charge distribution, and hydrophobic surface exposure. The integration of these tools into automated high-throughput formats has substantially compressed the timeline from initial hit identification to the nomination of development candidates with confirmed manufacturability attributes.⁸

Outlook for biologics and antibody discovery screening

The next generation of biologics screening platforms will increasingly converge with artificial intelligence and machine learning to guide library design, predict candidate properties, and prioritize hits for experimental follow-up. Generative protein language models trained on large antibody sequence databases are already being applied to de novo antibody design, proposing candidate sequences that have not been observed in natural immune repertoires and that can be synthesized and screened without constructing a physical library. This shift from selection-based to prediction-based discovery has the potential to dramatically reduce the number of candidates requiring experimental evaluation.

The expansion of biologic modalities beyond conventional mAbs — encompassing bispecific antibodies, antibody-drug conjugates, nanobodies, and multispecific fusion proteins — will continue to drive demand for screening platforms capable of assessing complex, multicomponent constructs in functionally relevant assay formats. As the complexity of the biologic drug development pipeline increases, the ability to screen larger, more diverse candidate sets at earlier stages, while simultaneously assessing functional potency and biophysical developability, will be central to improving the efficiency and success rate of biologics discovery.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.